Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 1883 | 19.14 |
09:36 ET | 100 | 19.2 |
09:43 ET | 100 | 19.17 |
09:48 ET | 600 | 19.09 |
09:50 ET | 200 | 19.125 |
09:52 ET | 900 | 19.17 |
09:57 ET | 100 | 19.18 |
10:01 ET | 200 | 19.18 |
10:03 ET | 200 | 19.26 |
10:06 ET | 100 | 19.225 |
10:10 ET | 200 | 19.23 |
10:12 ET | 100 | 19.225 |
10:14 ET | 626 | 19.19 |
10:15 ET | 100 | 19.19 |
10:17 ET | 200 | 19.19 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 225.2x | --- |
Ginkgo Bioworks Holdings Inc | 1.1B | -1.1x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -5.9x | --- |
Dynavax Technologies Corp | 1.6B | 240.0x | --- |
MannKind Corp | 1.3B | 190.1x | --- |
Zai Lab Ltd | 1.9B | -5.7x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 225.2x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | 124.5x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.